Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.
WARRINGTON, Pa., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.
| Ladenburg Thalmann Healthcare Conference | |
| Format: | Company presentation and 1x1 investor meetings |
| Date: | Thursday, September 29, 2022 |
| Time: | 4:00 p.m. ET |
| Location: | Sofitel Hotel, New York, NY |
| Webcast Link: | Click Here |
To schedule a meeting with the Company, please contact your Ladenburg Thalmann representative.
A live webcast and replay will also be available under the Events section of the Company’s Investor relation website (https://ir.windtreetx.com/events).
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com
Media contact:
Katie Larch / Robert Flamm, Ph.D.
Burns McClellan, Inc.
klarch@burnsmc.com / rflamm@burnsmc.com
